Harvard BioscienceHBIO
13F holders, Q1 2026 (March 31)3holders −60
0new positions
28sold out
$4.87avg. 13F price*
At the end of Q1 2026, 3 institutions reported holding Harvard Bioscience Inc. (HBIO) in their 13F filings, down 60 from Q4 2025. 0 opened new positions and 28 sold out. The largest holders were Meros Investment Management, LP ($577K), Nano Cap New Millennium Growth Fund L P ($572K) and Financial Connections Group, Inc. ($0).
- Company
- Harvard Bioscience Inc.
- CUSIP
- 416906105
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 28 | $932K |
All 13F filers, Q4 2025 → Q1 2026: 2,975,156 shares sold, net −2,975,156 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 3 holders
| Meros Investment Management, LP | 0.25% | Reduce -90.3% | 118,522 | $577K |
| Nano Cap New Millennium Growth Fund L P | 0.54% | Reduce -80.4% | 117,500 | $572K |
| Financial Connections Group, Inc. | 0.00% | Reduce -90.0% | 30 | $0 |
"% of holder's portfolio" is HBIO's weight in each manager's 13F, not the share of Harvard Bioscience Inc. the manager owns.